Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513627 | 1.00 | PPARG (0.47) | PPARGALDH1A1NFE2L2LMNACA1 | |
| SCHEMBL5973925 | 1.00 | PPARG (0.47) | PPARGALDH1A1NFE2L2LMNACA1 | |
| SCHEMBL827214 | 0.88 | CA1 (0.41) | PPARGALDH1A1NFE2L2LMNACA1 | |
| SCHEMBL827663 | 0.88 | PPARG (0.50) | PPARGALDH1A1NFE2L2CA1CA2 | |
| SCHEMBL1194566 | 0.88 | PPARG (0.50) | PPARGALDH1A1LMNACA1CA2 | |
| SCHEMBL1194129 | 0.88 | PTGES2 (0.43) | PPARGALDH1A1CA1CA2MMP1 | |
| SCHEMBL826798 | 0.88 | KMT2A (0.50) | ALDH1A1NFE2L2LMNACA1CA2 | |
| SCHEMBL1194564 | 0.88 | PPARG (0.50) | PPARGALDH1A1LMNACA1CA2 | |
| SCHEMBL827215 | 0.88 | CA1 (0.41) | PPARGALDH1A1NFE2L2LMNACA1 | |
| SCHEMBL1194476 | 0.88 | PPARG (0.50) | PPARGALDH1A1NFE2L2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025240673-A1 | CANCER TREATMENT USING AKT INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-11-20 | — | — | WO | claimed |
| CN-120202002-A | Pharmaceutical composition for treating cancer | 微境生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2025029980-A1 | INHIBITION OF HYPOXIA SIGNALING PATHWAY BY PLK1 INHIBITOR | CARDIFF ONCOLOGY, INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-20250017933-A1 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. | 2025-01-16 | — | — | US | claimed |
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. | 2024-06-20 | — | — | US | claimed |
| WO-2024114730-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER | 微境生物医药科技(上海)有限公司 | 2024-06-06 | — | — | WO | claimed |
| EP-4319729-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2023158514-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-24 | — | — | WO | claimed |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-08-24 | — | — | US | claimed |
| US-20190125765-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2019-05-02 | — | — | US | claimed |
| US-10155006-B2 | Combination therapies and methods of use thereof for treating cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-12-18 | — | — | US | claimed |
| CN-104230770-B | The application of styryl sulfone compound, its preparation method as well as neuroprotective agent | 华夏生生药业(北京)有限公司 | 2017-11-21 | — | — | CN | claimed |
| US-20170216317-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-03 | — | — | US | claimed |
| US-9566280-B2 | Combination therapies and methods of use thereof for treating cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-02-14 | — | — | US | claimed |
| WO-2015116696-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-08-06 | — | — | WO | claimed |
| US-20150209359-A1 | Combination Therapies and Methods of Use Thereof for Treating Cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-07-30 | — | — | US | claimed |
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | claimed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | claimed |
| US-20090123934-A1 | Inhibition of polo kinase by matrimony maintains G2 arrest in the meiotic cell cycle | STOWERS MEDICAL INSTITUTE INC. | 2009-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | PPARG 2123/4885ALDH1A1 926/4885NFE2L2 444/4885 |
| US-20250017933-A1 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | PLK1, KDM1B, EZH2 | PPARG 2882/4885ALDH1A1 1850/4885NFE2L2 1940/4885 |
| US-20240197730-A1 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK2, CHEK1 | PPARG 4067/4885ALDH1A1 2780/4885NFE2L2 3302/4885 |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | PLK2, PLK4, PLK1 | PPARG 2610/4885ALDH1A1 3772/4885NFE2L2 2263/4885 |
| US-20150209359-A1 | Combination Therapies and Methods of Use Thereof for Treating Cancer | PLK2, KLK3, PLK3 | PPARG 428/4885ALDH1A1 1304/4885NFE2L2 1397/4885 |
| US-20170216317-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | PLK2, KLK3, PLK3 | PPARG 428/4885ALDH1A1 1304/4885NFE2L2 1397/4885 |
| US-10155006-B2 | Combination therapies and methods of use thereof for treating cancer | PLK2, KLK3, PLK3 | PPARG 428/4885ALDH1A1 1304/4885NFE2L2 1397/4885 |
| US-20190125765-A1 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | PLK2, KLK3, PLK3 | PPARG 428/4885ALDH1A1 1304/4885NFE2L2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.